Are there antibody-drug conjugates approved for Ampullary Cancer

Q: Are there antibody-drug conjugates approved for Ampullary Cancer

Based on current evidence, there are no ADCs specifically FDA-approved exclusively for ampullary cancer. However, this is an important area to explore with your oncology team, as the treatment landscape for ampullary cancer is evolving. According to NCCN Guidelines for Small Bowel Adenocarcinoma which includes ampullary cancer as a periampullary tumor, the recommended systemic therapies focus primarily on: - Chemotherapy regimens FOLFOX, CAPEOX, FOLFIRI with or without bevacizumab - Targeted the

Ampullary_cancerMay 23, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Antibody-Drug Conjugates (ADCs) for Ampullary Cancer

Based on current evidence, there are no ADCs specifically FDA-approved exclusively for ampullary cancer. However, this is an important area to explore with your oncology team, as the treatment landscape for ampullary cancer is evolving.

What We Know About ADCs in Similar Cancers

According to NCCN Guidelines for Small Bowel Adenocarcinoma (which includes ampullary cancer as a periampullary tumor), the recommended systemic therapies focus primarily on:

Chemotherapy regimens (FOLFOX, CAPEOX, FOLFIRI with or without bevacizumab)
Targeted therapies based on specific mutations (BRAF V600E, NTRK fusions, RET fusions, HER2-amplified tumors)
Immunotherapy for patients with specific biomarkers (MSI-H/dMMR or high tumor mutational burden)

ADCs in Related GI Cancers

While not standard for ampullary cancer specifically, ADCs like fam-trastuzumab deruxtecan (T-DXd/Enhertu) have shown activity in HER2-amplified gastrointestinal cancers. According to NCCN Guidelines, T-DXd is recommended for HER2-amplified tumors in small bowel adenocarcinoma.

What This Means for You

Key questions to ask your oncology team:

Has my tumor been tested for HER2 amplification or overexpression?
Are there any other biomarkers (NTRK, RET, BRAF mutations) that might make me eligible for targeted therapies or ADCs?
Are there clinical trials available that are testing ADCs in ampullary cancer?
Would my tumor profile make me eligible for off-label use of any ADC therapies?

Your oncologist can review your specific pathology results and molecular testing to determine if any ADC-based approaches might be appropriate for your individual case.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Upload Records →Ask About Your Case →